Insmed Inc – ‘8-K’ for 2/27/01

On:  Wednesday, 2/28/01, at 10:51am ET   ·   For:  2/27/01   ·   Accession #:  927356-1-252   ·   File #:  0-30739

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4     10K 
 2: EX-99.1     Press Release                                          4     13K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  

FORM 8-K  

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) 
OF THE SECURITIES EXCHANGE ACT OF 1934  

Date of report (Date of earliest event reported): February 27, 2001 

INSMED INCORPORATED 
(Exact name of registrant as specified in its charter)  

                                                        [Enlarge/Download Table]
                                                                                       
           VIRGINIA                         0-30739              54-1972729            
---------------------------------------------------------------------------------------
(State or other jurisdiction of    (Commission File Number)      (I.R.S. Employer      
         incorporation)                                          Identification No.)   

800 East Leigh Street, Richmond, VA 23219 
(Address of principal executive offices and zip code) 

Registrant's telephone number, including area code: (804) 828-6893  

8-K
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
ITEM 5. OTHER EVENTS                                                            

On February 27, 2001, Insmed Incorporated issued a press release
        announcing the results in two key Phase II clinical trials, one in obese
        women with polycystic ovarian syndrome (PCOS) and one in dyslipidemia in
   non-diabetic subjects, for its lead oral insulin sensitizer, INS-1.
        Insmed also announced in the press release that Insmed's management team
      will host a conference call on Wednesday, February 28 at 9:00 a.m. EST
       to discuss these results. The dial-in number is 800-289-0493 (domestic)
       or 913-981-5510 (international). The reference code is 433360. A replay
      of the call will be available from 12:00 p.m. EST, Wednesday, February
       28 through 12:00 p.m. EST, Wednesday, March 7, 2001. The replay dial-in
    number is 888-203-1112 (domestic) or 719-457-0820 (international). A
   copy of the press release is attached hereto as Exhibit 99.1 and is
      incorporated herein by reference. The press release was also posted on
Insmed's website on February 27, 2001.                          

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS      

(c)     Exhibit                                                                 

99.1       Press Release dated February 27, 2001.           

8-K
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
SIGNATURES  

  Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the        
undersigned hereunto duly authorized.                                           

         INSMED INCORPORATED

Date: February 28, 2001            By:  /s/ Michael D. Baer                     
                         -------------------------
               Michael D. Baer
                       Chief Financial Officer

8-K
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
INSMED INCORPORATED 
INDEX TO EXHIBITS 

Exhibit Number                                                                  

99.1  Press Release dated February 27, 2001.                                    

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
		3/7/01		2					None on these Dates
Filed on:		2/28/01		3
For Period End:		2/27/01		1		4
									List all Filings